Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Precision BioSciences, Inc.

< Previous 1 2 3 4 5 Next >
Precision BioSciences to Report First Quarter 2022 Financial Results on May 9, 2022
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Fourth Quarter and Fiscal Year 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at the 40th Annual J.P. Morgan Health Care Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Completes Spin-Out of Elo Life Systems
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Clinical Program Updates for Its Allogeneic CAR T Pipeline
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Host Virtual Webcast and Conference Call to Review Interim Phase 1/2a PBCAR0191 CAR T Data and Provide CAR T Program Updates on Saturday, December 11, 2021
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present Preclinical Gene Editing Data on its ARCUS-Based Chronic Hepatitis B Program at the HEP DART 2021 Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Third Quarter 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Highlight Capabilities of ARCUS Gene Editing for Allogeneic CAR T Cell Immunotherapies at The Society for Immunotherapy of Cancer 36th Annual Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Appoints Sam Wadsworth, Ph.D. and Shari Lisa Piré, J.D. to Board of Directors
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Two Oral Presentations Highlighting Updated Interim Data from Lead PBCAR0191 CAR T Immunotherapy for Relapsed and Refractory B-cell Malignancies at the 63rd Annual Meeting of the American Society of Hematology
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Third Quarter 2021 Financial Results on November 10, 2021 and Participate in the Stifel 2021 Virtual Healthcare Conference on November 16, 2021
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at the Jefferies Virtual Gene Therapy/Editing Summit on Thursday, October 27, 2021
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces Grant of Inducement Award for Newly Appointed Chief Executive Officer Pursuant to Nasdaq Listing Rule 5635(c)(4)
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Appoints Michael Amoroso Chief Executive Officer
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present at H.C. Wainwright 23rd Annual Global Investment Conference
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Outlines Clinical Development Strategy for In Vivo Gene Editing Pipeline
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences and iECURE Announce License and Collaboration Agreement to Develop ARCUS-Based Gene Editing Therapies
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences and Tiziana Life Sciences Announce Exclusive License Agreement to Evaluate Foralumab, a Novel, Fully Human Anti-CD3 Monoclonal Antibody, in Conjunction with Allogeneic CAR T Candidates for Cancer Treatment
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL TLSA
Precision BioSciences to Host In Vivo Gene Editing R&D Event on September 9, 2021
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports Second Quarter 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Report Second Quarter 2021 Financial Results on August 12, 2021
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Doses First Patient in Phase 1 Allogeneic CAR T Clinical Trial of PBCAR19B Immune Evading Stealth Cell for Relapsed/Refractory Non-Hodgkin Lymphoma
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL SWTX
Precision BioSciences Reports Progress on Two Strategies Designed to Optimize Durability of Allogeneic CAR T Therapy in R/R Non-Hodgkin Lymphoma
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Announces New Study Published in Nature Communications Using Engineered ARCUS Nuclease to Target Mutant Mitochondrial DNA In Vivo
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Appoints Alex Kelly as Chief Financial Officer
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences to Present Data from its First Generation CD19 Allogeneic CAR T Program in Relapsed/Refractory Non-Hodgkin Lymphoma at the 2021 American Society of Clinical Oncology Meeting
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
Precision BioSciences Reports First Quarter and 2021 Financial Results and Provides Business Update
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
New Preclinical Data Presented at the 2021 American Society of Genetic & Cell Therapy Annual Meeting Highlights Precision BioSciences’ ARCUS In Vivo Genome Editing
From Precision BioSciences, Inc.
Via Business Wire
Tickers DTIL
< Previous 1 2 3 4 5 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.